ERBB2 and breast carcinoma: In addition, another approach that has been used is to combine the anti-HER2 antibody trastuzumab with a bispecific MM-11 mAb anti-ErbB2/anti-ErbB3 mAb (241) for the treatment of HER2+ breast cancer (NCT01097460).